A new study would be done to evaluate a lower dosage that performed better than higher dose in AstraZeneca’s studies, that will be an additional global trial to assess the efficacy of its COVID-19 vaccine. AstraZeneca’s, Chief Executive Pascal Soriot has been quoted saying this to the Bloomberg media.
According to the Bloomberg News report, Soriot said the efficacy of the vaccine is high so the global trial will be done on the less patients “International study, but this one could be faster because we know efficacy is high so we need a smaller number of patients.”
